ArticleScientific reports2025
SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate adenocarcinoma (PRAD) remains a leading cause of cancer-related mortality in men, highlighting an urgent need to identify novel prognostic biomarkers and therapeutic targets. While the role of solute carrier family genes in tumorigenesis has become increasingly well-defined, the function of the transmembrane transporter SLC45A2 in PRAD progression and immune regulation remains unclear. Transcriptomic data from 499 PRAD tumors and 52 normal tissues in the TCGA-PRAD database were integrated. Differentially expressed genes were screened using DESeq2, and independent prognostic genes were identified via Cox regression analysis (adjusted for age, TNM stage, and metastasis status). The expression of SLC45A2 in PRAD cell lines was verified by qRT-PCR and Western blot. CCK-8, wound-healing, and Transwell assays were performed to evaluate the effects of SLC45A2 on cell proliferation and migration. The infiltration levels of 24 immune cell types were analyzed using the ssGSEA algorithm. IHC and HPA database validated tissue-level protein expression. In vivo experiment was xenograft tumor model. The immunomodulatory role of SLC45A2 was explored via co-culture experiments of DU145 cells and CD8⁺T cells. SLC45A2 was identified as an independent prognostic factor for PRAD. Its mRNA and protein levels were significantly upregulated in tumor tissues compared to normal tissues. Functional experiments showed that SLC45A2 knockdown inhibited the proliferation and migration of LNCaP and DU145 cells, while SLC45A2 overexpression reversed these effects. Mechanistically, SLC45A2 promoted PRAD cell proliferation by activating the PI3K/AKT pathway and mediated immune evasion by impairing the cytotoxic effect of CD8⁺T cells. SLC45A2 drives PRAD progression via dual oncogenic mechanisms: direct promotion of tumor proliferation and migration, and suppression of cytotoxic immune cell infiltration, confirming that SLC45A2 can serve as a potential prognostic biomarker and therapeutic target for advanced PRAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.